Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer By Ogkologos - December 19, 2025 560 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from an updated analysis of the EMBER-3 study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR FDA Approves Alpelisib for PIK3CA-Related Overgrowth Spectrum April 13, 2022 Adding Gedatolisib to Fulvestrant, with or without Palbociclib, Improves PFS in... March 17, 2026 Study Shows that Disrupted Gut Bacteria May Contribute to the Spread... June 21, 2019 “My Heart Will Always Hurt”: How I Honor My Childhood Best... April 26, 2022 Load more HOT NEWS Second- or Third-Line Treatment with Tisotumab Vedotin Results in Greater Efficacy... Selpercatinib Shows Durable Efficacy in RET-Altered Thyroid Cancer Study Shows Supplements Increase Risk of Relapse and Death in Breast... 7 ways we’ve influenced progress in lung cancer
